In February 2025, AREX Biosciences, Ltd (AREX) and Umibio Science and Technology Co., Ltd (Umibio) officially entered into a strategic partnership through a signed cooperation agreement, marking a significant milestone in the international market development of exosome-related products. This collaboration has garnered substantial attention within the biotechnology sector.

Amidst the rapid growth of the global biotechnology industry, exosomes have demonstrated immense potential in cutting-edge fields such as disease diagnosis, therapeutic applications, and drug delivery systems. The increasing demand for precision medicine has created expansive opportunities for the exosome market, which is experiencing accelerated market expansion. Against this backdrop of industry opportunities, the collaboration between AREX and Umibio holds exceptional significance.

Under this partnership, both companies will enter the international market under a joint brand strategy. AREX will leverage its established global distribution network and professional marketing capabilities to conduct in-depth market research, develop targeted market strategies, and actively expand international sales channels for exosome products. Umibio, with its profound R&D expertise and rigorous production and delivery systems, will continuously optimize and upgrade products based on market feedback and cutting-edge scientific research, ensuring timely and high-quality delivery while providing comprehensive technical support for AREX's marketing initiatives.

The joint brand strategy effectively combines the complementary strengths and brand characteristics of both companies, creating a powerful brand synergy in the international market that enhances product recognition and competitiveness. This collaboration not only facilitates the integration of industry resources and accelerates the internationalization of exosome products but also promotes innovative development across the entire sector. Looking ahead, AREX and Umibio will maintain close cooperation, actively exploring additional application scenarios for exosomes, thereby contributing to the advancement of global biotechnology and the improvement of human health. 

About AREX Biosciences, Ltd

AREX Biosciences was founded by a team of seasoned sales and tech veterans who share a common vision: Energize your Science. With a focus on antibody-based life sciences products and services, our expertise and commitment drive us to create high-performance, cost-effective solutions that empower researchers across the globe. Our goal is to set new industry standards, continuously striving to lead and innovate within the biotechnology sector.

Contact       400-886-0853     /      www.arexbio.com       /       info@arexbio.com

About Umibio Science and Technology Co., Ltd

Umibio Science and Technology is a high-tech company specializing in exosome product development and technical services. Founded in 2015 in Zhangjiang High-Tech Park, Shanghai, it is a company engaged in exosome research, service and related reagent development in China, and has now developed into a supplier of exosome drug delivery and reagent solutions.

The company has 2,000 square meters of GMP standard factory workshop, instruments, facilities and equipments, having realized standardized and large-scale production and laying a solid foundation for entering the market.

Contact       4006-166-973     /      en.umibiotech.cn       /       umibio@umibio.cn